8-K - Humacyte, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Humacyte, Inc. entered into securities purchase agreements on March 19, 2026, to issue and sell 25,000,000 shares of common stock at $0.80 per share in a registered direct offering, expecting gross proceeds of $20 million and net proceeds of approximately $18.4 million after fees and expenses. The proceeds will fund Symvess commercialization in vascular trauma, a hemodialysis BLA supplement, Phase 3 results readout, pipeline development, and general corporate purposes.

Key Takeaways

1Entered Purchase Agreements for 25,000,000 shares at $0.80 per share, gross $20 million

2Net proceeds approximately $18,400,000 after placement agent fees

3Placement Agent: Titan Partners Group LLC (6% fee)

4Expected closing on or about March 20, 2026, subject to customary conditions

5Offering pursuant to S-3 registration (File No. 333-290231)

6Led by new life science dedicated investor and long-only mutual fund

Current Report Details

Event Type

Material Agreement

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

. Entry into a Material Definitive Agreement. On March 19, 2026, Humacyte, Inc. (the “Company”) entered into certain securities purchase agreements (the “Purcha

Material Agreement

$18.4M

Source Document

7.01

shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 5.1 Opinion of Covington & Burling LLP. 10.1 Form of Securities Purchase Agreement

Exhibits Only

Source Document

Transaction Details

Material Agreement

Agreement: Purchase Agreements
Parties: Humacyte, Inc., certain investors

•Issue and sell 25,000,000 shares of common stock, $0.0001 par value, at $0.80 per share
•Net proceeds approximately $18,400,000 after placement agent fees and estimated expenses
•Closing expected on or about March 20, 2026, subject to customary closing conditions
•Placement Agreement with Titan Partners Group LLC, who uses reasonable best efforts to sell shares
•Customary representations, warranties, conditions, indemnification, and termination provisions

Exhibits (5)

10.1

EXHIBIT 10.1

10.2

EXHIBIT 10.2

5.1

EXHIBIT 5.1

8-K

FORM 8-K

99.1

EXHIBIT 99.1